New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
08:32 EDTANAC, SPPIAnacor appoints Paul L. Berns as CEO, effective immediately
Berns succeeds David P. Perry who has served as Anacorís (ANAC) President and CEO since 2002. Berns has over 20 years of industry experience as an executive in biotechnology and pharmaceutical companies. He most recently served as the President and Chief Executive Officer of Allos Therapeutics prior to its acquisition by Spectrum Pharmaceuticals (SPPI) in 2012.
News For ANAC;SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2015
09:17 EDTSPPICourt lifts injunction on sales of generic copy of Spectrum's Fusilev
The U.S. Court of Appeals for the Federal Circuit yesterday issued an order that lifted a temporary injunction put in place March 6 that had blocked Novartis' (NVS) Sandoz unit from selling a generic version of Spectrum Pharmaceuticals' (SPPI) colorectal cancer treatment Fusilev. The appeals court ruled that Spectrum failed to meet the requirements for an injunction pending appeal.
09:00 EDTSPPISpectrum revenue under 'major threat' after ruling, says Roth Capital
Roth Capital says an appeals court ruling yesterday denying Spectrum's injunction motion aimed to block Sandoz's generic Fusilev launch represents a "major threat" to Spectrum's revenue stream. Roth expects erosion of the company's Fusilev sales once the generic is launched and maintained a Neutral rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use